Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized 6-mercaptopurine in pediatric ALL
NCT04228393Phase 3Unknown
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mercaptopurine in acute lymphoblastic leukemia (ALL). Primary endpoints: Leukopenia at 6 weeks and Thiopurine-induced leukopenia at 6 weeks. Status: unknown.
02
Drugs
mercaptopurine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04228393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228393.